Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has begun recruitment for its Phase 2 clinical trial of the Company’s lead oncology agent PV-10 at a sixth major center located at the California Pacific Medical Center, in San Francisco, CA. David Minor, M.D. will serve as principal investigator at the new center covering the western United States.
Original post by Dermatology News From Medical News Today
A recent clinical study found that patients experienced nearly a 70% reduction in pain when MPM Medical Inc.’s Regenecare HA® hydrogel was used prior to and during the changing of their wound dressings. The finding comes at a time when a cross-section of American thought leaders are calling the lack of proper pain management a national healthcare crisis. In answer, members of Congress have united to sponsor the National Pain Care Policy Act of 2008 (H.R.
Original post by Dermatology News From Medical News Today
Michelson Diagnostics has announced that it will demonstrate its prototype multi-beam Optical Coherence Tomography (OCT) probe at the BIOS Exhibition at SPIE Photonics West, San Jose, 24-25th January 2009 (Stand 8731). More than one variant of the new probe will be launched later in 2009, including a dermal version (with X-Y scanning, to enable 3D mapping of skin lesions) and a version equipped with a rigid endoscope, suitable for oral applications.
Original post by Dermatology News From Medical News Today
Copyright 2006-2008 Skin Clinics Network | Terms of Service